Precision Medicine

With $2.1M in funding, Mave Health's new tDCS wearable claims to rewire your brain for focus and calm. But does the science support the hype?

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

How Robert Wood Johnson University Hospital eliminated a two-month backlog for sleep apnea testing, transforming patient care and offering a new healthcare model.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

With late-breaking hypertension data and an AI-driven platform, Kardigan is set to showcase a new, personalized approach to cardiovascular medicine.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

After regaining Nasdaq compliance, Incannex Healthcare is leveraging its $75M war chest to advance novel treatments for sleep apnea and anxiety.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

Galectin Therapeutics adds legendary neurosurgeon Dr. Henry Brem to its board, a strategic move to leverage his drug development expertise for its lead liver drug.

Princess Padmaja Kumari Parmar receives the Mary Tyler Moore Award for her advocacy, bridging a legacy of hope with a modern fight for global T1D equity.

The biotech reports promising clinical data for its lead alpha-therapy program and secures funding into late 2027, navigating a high-cost, high-reward path.

With promising clinical data for its lead drug silevertinib and a strong new financial position, Black Diamond Therapeutics charts a dual course for two deadly cancers.

A new prenatal vitamin tackles the 'choline gap,' a nutrient deficiency affecting 90% of pregnant women that is crucial for fetal brain development.

As MediciNova execs meet investors at the ROTH Conference, all eyes are on pivotal updates for its ALS, MS, and NAFLD drug candidates.

As maternity care deserts expand, one rural hospital is using wearable tech to bring vital prenatal monitoring to high-risk mothers right in their homes.

From experimental surgeries to robotic precision, see how UCHealth's 60-year journey transformed organ transplantation and gave 10,000 people a new life.

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

As employers grapple with soaring obesity drug costs, a new partnership aims to offer predictable pricing and comprehensive care. Here's how it works.

With a $35 million boost from RA Capital, Equillium extends its cash runway to 2029, fueling the clinical development of its promising oral UC therapy, EQ504.